Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Condition: Non-Small Cell Lung Cancer
NCT07329322
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.